Table 1.
Study Demographics for Study Completers
| Nominal relative D-serine dose (mg/kg/d) | 30mg/kg (n=12) | 60 mg/kg (n=19) | 120 mg/kg (n=16) |
|---|---|---|---|
| Age | 41.7±11.4 | 43.5±9.4 | 43.2±9.6 |
| Male (%) | 75% | 95% | 88% |
| Schizophrenia (n) | 9 | 16 | 13 |
| Schizoaffective (n) | 3 | 3 | 3 |
| Inpatient (n) | 5 | 8 | 6 |
| Highest Education | 12.1±2.3 | 11.7±1.9 | 11.9±2.8 |
| Age of 1st Treatment | 21.9±5.4 | 21.1±6.4 | 20.8±8.9 |
| Age of 1st Hospitalization1 | 22.3±4.5 | 22.6±5.4 | 24.0±8.6 |
| Antipsychotic dose (CPZ Equivalents/d) | 468.8±252 | 602.6±295 | 493.7±319 |
| Atypical (%) | 67% | 68% | 75% |
| Dose Repeaters | N/A | 5 | 8 |
| Body weight (kg) | 88.9±17.2 | 99.8±17.5 | 99.5±21.0 |
| Achieved absolute D-serine dose (g/d) | 2.58±0.31 | 5.58±0.45 | 11.1±1.1 |
Except for number of dose repeaters, there were no significant baseline differences on a one-way ANOVA (all p>0.29).
1
Data unavailable for one patient in 30 mg/kg dose and one in 120 mg/kg dose.